Performance of FDA-Approved AI Algorithms in Detecting Acute Pulmonary Embolism on Computed Tomographic Pulmonary Angiography (CTPA): A Meta-Analysis of Real-World Retrospective Studies

FDA批准的AI算法在计算机断层扫描肺动脉造影(CTPA)中检测急性肺栓塞的性能:一项基于真实世界回顾性研究的荟萃分析

阅读:1

Abstract

Pulmonary embolism (PE) is a potentially fatal condition requiring prompt and accurate diagnosis. Computed tomographic pulmonary angiography (CTPA) is the gold standard for PE detection, but its interpretation is time-intensive and subject to human error. Recent advancements in artificial intelligence (AI), particularly in machine learning (ML) and deep learning (DL) algorithms, offer promising tools to enhance diagnostic efficiency and accuracy. This systematic review and meta-analysis evaluated the diagnostic performance of FDA-approved ML algorithms for detecting acute PE on CTPA. A comprehensive literature search across six databases identified six retrospective studies encompassing 9,102 CTPA scans, all of which assessed either the Aidoc or CINA-PE algorithms. Pooled sensitivity and specificity were 93% (95% CI: 88%-95%) and 98% (95% CI: 93%-100%), respectively, indicating high diagnostic accuracy across real-world datasets. All included studies demonstrated low risk of bias according to Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) assessments. These findings support the integration of FDA-approved ML tools into radiological workflows as adjuncts to reduce diagnostic errors and improve triage. However, prospective trials are needed to assess their impact on clinical decision-making, workflow efficiency, cost-effectiveness, and patient outcomes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。